Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma
NK Gerber, Y Yamada, A Rimner, W Shi… - International Journal of …, 2014 - Elsevier
Purpose/Objectives Radiation therapy (RT) is the principal modality in the treatment of
patients with brain metastases (BM). However, given the activity of EGFR tyrosine kinase …
patients with brain metastases (BM). However, given the activity of EGFR tyrosine kinase …
Erlotinib Versus Radiation Therapy for Brain Metastases in Patients With EGFR-Mutant Lung Adenocarcinoma
NK Gerber, Y Yamada, A Rimner, W Shi… - International Journal of …, 2014 - redjournal.org
Purpose/Objectives Radiation therapy (RT) is the principal modality in the treatment of
patients with brain metastases (BM). However, given the activity of EGFR tyrosine kinase …
patients with brain metastases (BM). However, given the activity of EGFR tyrosine kinase …
[HTML][HTML] Erlotinib versus Radiation Therapy for Brain Metastases in Patients with EGFR-Mutant Lung Adenocarcinoma
NK Gerber, Y Yamada, A Rimner, W Shi… - … journal of radiation …, 2014 - ncbi.nlm.nih.gov
Results 222 patients were identified. Exclusion criteria included prior erlotinib use, presence
of a de novo erlotinib resistance mutation, or incomplete data. Of the remaining 110 patients …
of a de novo erlotinib resistance mutation, or incomplete data. Of the remaining 110 patients …
Erlotinib Versus Radiation Therapy for Brain Metastases in Patients With EGFR-Mutant Lung Adenocarcinoma
NK Gerber, Y Yamada, A Rimner, W Shi… - International Journal of …, 2014 - inis.iaea.org
[en] Purpose/Objectives: Radiation therapy (RT) is the principal modality in the treatment of
patients with brain metastases (BM). However, given the activity of EGFR tyrosine kinase …
patients with brain metastases (BM). However, given the activity of EGFR tyrosine kinase …
Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma.
NK Gerber, Y Yamada, A Rimner, W Shi… - … Journal of Radiation …, 2014 - europepmc.org
Results 222 patients were identified. Exclusion criteria included prior erlotinib use, presence
of a de novo erlotinib resistance mutation, or incomplete data. Of the remaining 110 patients …
of a de novo erlotinib resistance mutation, or incomplete data. Of the remaining 110 patients …
Erlotinib Versus Radiation Therapy for Brain Metastases in Patients With EGFR-Mutant Lung Adenocarcinoma
NK Gerber, Y Yamada, A Rimner, W Shi… - International Journal of …, 2014 - osti.gov
Purpose/Objectives: Radiation therapy (RT) is the principal modality in the treatment of
patients with brain metastases (BM). However, given the activity of EGFR tyrosine kinase …
patients with brain metastases (BM). However, given the activity of EGFR tyrosine kinase …
Erlotinib Versus Radiation Therapy for Brain Metastases in Patients With EGFR-Mutant Lung Adenocarcinoma
NK Gerber, Y Yamada, A Rimner, W Shi… - International Journal of …, 2014 - infona.pl
Radiation therapy (RT) is the principal modality in the treatment of patients with brain
metastases (BM). However, given the activity of EGFR tyrosine kinase inhibitors in the …
metastases (BM). However, given the activity of EGFR tyrosine kinase inhibitors in the …
Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma
NK Gerber, Y Yamada, A Rimner… - … journal of radiation …, 2014 - pubmed.ncbi.nlm.nih.gov
Purpose/objectives Radiation therapy (RT) is the principal modality in the treatment of
patients with brain metastases (BM). However, given the activity of EGFR tyrosine kinase …
patients with brain metastases (BM). However, given the activity of EGFR tyrosine kinase …